ATE430937T1 - Plasma urotensin und menschliche herzerkrankung - Google Patents

Plasma urotensin und menschliche herzerkrankung

Info

Publication number
ATE430937T1
ATE430937T1 AT03740791T AT03740791T ATE430937T1 AT E430937 T1 ATE430937 T1 AT E430937T1 AT 03740791 T AT03740791 T AT 03740791T AT 03740791 T AT03740791 T AT 03740791T AT E430937 T1 ATE430937 T1 AT E430937T1
Authority
AT
Austria
Prior art keywords
heart disease
human heart
urotensin
plasma
plasma urotensin
Prior art date
Application number
AT03740791T
Other languages
English (en)
Inventor
Leong Ng
Original Assignee
Inverness Medical Switzerland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0216505A external-priority patent/GB0216505D0/en
Application filed by Inverness Medical Switzerland filed Critical Inverness Medical Switzerland
Application granted granted Critical
Publication of ATE430937T1 publication Critical patent/ATE430937T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03740791T 2002-07-11 2003-07-11 Plasma urotensin und menschliche herzerkrankung ATE430937T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0216191.7A GB0216191D0 (en) 2002-07-11 2002-07-11 Plasma urotensin in human heart failure
GBGB0216500.9A GB0216500D0 (en) 2002-07-11 2002-07-16 Plasma urotensin in human heart failure
GB0216505A GB0216505D0 (en) 2002-07-11 2002-07-17 Plasma urotensin in human heart failure
PCT/GB2003/003011 WO2004008140A2 (en) 2002-07-11 2003-07-11 Plasma urotensin in human heart failure

Publications (1)

Publication Number Publication Date
ATE430937T1 true ATE430937T1 (de) 2009-05-15

Family

ID=9940317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740791T ATE430937T1 (de) 2002-07-11 2003-07-11 Plasma urotensin und menschliche herzerkrankung

Country Status (11)

Country Link
US (1) US20040077027A1 (de)
EP (1) EP1521967B1 (de)
JP (1) JP4602078B2 (de)
CN (1) CN100582782C (de)
AT (1) ATE430937T1 (de)
AU (1) AU2003281071B2 (de)
CA (1) CA2492787A1 (de)
DE (1) DE60327530D1 (de)
GB (2) GB0216191D0 (de)
IL (2) IL166194A0 (de)
WO (1) WO2004008140A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074194B2 (en) * 2003-05-19 2006-07-11 Ischemia Technologies, Inc. Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
CN101185000A (zh) * 2005-03-29 2008-05-21 因弗因斯医药瑞士股份有限公司 监测患者的方法和装置
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
EP1910843A2 (de) * 2005-07-11 2008-04-16 Inverness Medical Switzerland GmbH Assay
CN106908603B (zh) * 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
JP5081930B2 (ja) * 2007-03-08 2012-11-28 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｓｌｉｍ−１の使用
WO2010043393A1 (en) * 2008-10-17 2010-04-22 Roche Diagnostics Gmbh Use of biglycan in the assessment of heart failure
WO2015175502A2 (en) * 2014-05-12 2015-11-19 Palatin Technologies, Inc. Replacement therapy for natriuretic peptide deficiencies
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
WO2025040754A1 (en) * 2023-08-22 2025-02-27 Roche Diagnostics Gmbh Monitoring of cardiovascular markers in interstitial fluid and its application in assessment of heart failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710008B1 (en) * 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
JP5264026B2 (ja) * 1997-06-10 2013-08-14 エルパス・インコーポレイテッド 心疾患の早期発見のための方法
WO1999035266A2 (en) * 1998-01-09 1999-07-15 Smithkline Beecham Corporation Human urotensin ii
US6075137A (en) * 1998-01-09 2000-06-13 Smithkline Beecham Corporation Human urotensin II
PL204235B1 (pl) * 1999-01-29 2009-12-31 Roche Diagnostics Gmbh Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
EP1241479B1 (de) * 2001-03-12 2007-08-01 Immundiagnostik AG Verfahren zur Bestimmung von Urotensin II in Körperflüssigkeiten und Diagnose von kardiovaskulären Krankheiten

Also Published As

Publication number Publication date
JP2005532564A (ja) 2005-10-27
EP1521967B1 (de) 2009-05-06
US20040077027A1 (en) 2004-04-22
JP4602078B2 (ja) 2010-12-22
IL166194A0 (en) 2006-01-15
AU2003281071A1 (en) 2004-02-02
CA2492787A1 (en) 2004-01-22
GB0216500D0 (en) 2002-08-28
GB0216191D0 (en) 2002-08-21
WO2004008140A3 (en) 2004-05-06
CN1678912A (zh) 2005-10-05
AU2003281071B2 (en) 2007-12-13
WO2004008140A2 (en) 2004-01-22
IL166194A (en) 2010-11-30
CN100582782C (zh) 2010-01-20
DE60327530D1 (de) 2009-06-18
EP1521967A2 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
DE60327530D1 (de) Plasma urotensin und menschliche herzerkrankung
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
ATE468811T1 (de) Verfahren und system zur überwachung von beatmungen
FI20021145A0 (fi) Laitteisto elintoimintojen mittaamiseksi
WO2007072225A3 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
ATE406575T1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
DE50200029D1 (de) Medizinisches Instrument zum Spülen und/oder Saugen
FI20030547A0 (fi) Menetelmä ja järjestelmä sydänanalyysiä varten
EP1962946A4 (de) Verfahren und vorrichtung zur bestimmung der herzleistung in einem patienten
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
GB0217333D0 (en) System and method for solution based multiparameter analysis of analytes
FI20020584A7 (fi) Menetelmä havainnointialueen mittakaavan määrittämiseksi
EP1589980A4 (de) Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung
EP1474531A4 (de) Elektrophoresetest zur vorhersage eines krebsrisikos und der wirksamkeit und toxizität einer krebstherapie
FI20031678A0 (fi) Näytteen käsittelymenetelmä ja järjestely siihen
EP1540353A4 (de) Teststreifen und verfahren zur bestimmung der ldl-cholesterinkonzentration aus vollblut
EP1483407A4 (de) Therapie- und diagnoseverfahren
ATE498020T1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
ITMI20022743A1 (it) Metodo per la determinazione del rischio di comparsa, della presenza o del decorso di malattie tumorali.
AU2003299389A8 (en) PRP detection method using an aminoglycoside antibiotic
EP1567863A4 (de) Therapie- und diagnoseverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties